Hudock Inc’s Sarepta Therapeutics SRPT Stock Holding History

Hudock Inc’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-400	Closed	-$10K	–	615
2014 Q1	$10K	Buy	+400	New	+$10.2K	0.01%	374

Other funds holding SRPT

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Hudock Inc's SRPT Position: Q2 2014 in Review

Hudock Inc sold out of Sarepta Therapeutics (SRPT) in Q2 2014, closing a stake of 400 shares — an estimated $10K sold.

Hudock Inc first reported a position in SRPT in Q1 2014 and held it in 1 quarter. The position peaked at $10K in Q1 2014. 128 funds tracked by Wall St. Rank hold SRPT as of Q2 2014.

Hudock Inc reported no remaining Sarepta Therapeutics position as of Q2 2014 after selling out during the quarter.
Hudock Inc sold 400 Sarepta Therapeutics shares in Q2 2014, an estimated $10K.
Hudock Inc first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 1 quarter.
Hudock Inc's Sarepta Therapeutics position peaked at $10K in Q1 2014.
128 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2014.

Based on Hudock Inc's 13F filing for Q2 2014, filed 14 Aug 2014.